^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PDE3A overexpression

    i
    Other names: PDE3A, Phosphodiesterase 3A, CGMP-Inhibited 3',5'-Cyclic Phosphodiesterase A, CGI-PDE, Cyclic GMP-Inhibited Phosphodiesterase A, Phosphodiesterase 3A, CGMP-Inhibited, CGI-PDE A, CAMP Phosphodiesterase, Myocardial CGMP-Inhibited, CGI-PDE-A, HTNB
    Entrez ID:
    5139
    2ms
    First-in-human dose escalation study of the first-in-class PDE3A-SLFN12 complex inducer BAY 2666605 in patients with advanced solid tumors co-expressing SLFN12 and PDE3A. (PubMed, Clin Cancer Res)
    Despite the decreased PDE3A enzymatic inhibition profile of BAY 2666605, the occurrence of thrombocytopenia in treated patients, an on-target effect of the compound, precluded the achievement of a therapeutic window, consequently leading to trial termination.
    P1 data • Journal • Metastases
    |
    PDE3A (Phosphodiesterase 3A)
    |
    PDE3A overexpression
    |
    BAY2666605
    2ms
    Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia. (PubMed, Leukemia)
    In vivo combination treatment of leukemic animals with high PDE3A expression significantly reduced leukemia burden and prolonged survival time compared with single-drug and vehicle control treatments. Our findings suggest that combined ANA and IDA treatment is an innovative and promising therapeutic strategy for AML patients with high PDE3A expression.
    Journal
    |
    CASP3 (Caspase 3) • PDE3A (Phosphodiesterase 3A) • GSDME (Gasdermin E)
    |
    PDE3A overexpression
    |
    idarubicin hydrochloride